CIC
ESPR

Crawford Investment Counsel’s Esperion Therapeutics ESPR Stock Holding History

Crawford Investment Counsel’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$28.8K – 297
2025
Q1 		$28.8K Buy
+20,000
New +$36.9K ﹤0.01% 287

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crawford Investment Counsel's ESPR Position: Q2 2025 in Review

Crawford Investment Counsel sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 20,000 shares — an estimated $28.8K sold.

Crawford Investment Counsel first reported a position in ESPR in Q1 2025 and held it in 1 quarter. The position peaked at $28.8K in Q1 2025. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Crawford Investment Counsel reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Crawford Investment Counsel sold 20,000 Esperion Therapeutics shares in Q2 2025, an estimated $28.8K.
  • Crawford Investment Counsel first reported a position in Esperion Therapeutics in Q1 2025 and held it in 1 quarter.
  • Crawford Investment Counsel's Esperion Therapeutics position peaked at $28.8K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Crawford Investment Counsel's 13F filing for Q2 2025, filed 14 Aug 2025.